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Abstract As the lipidomics field continues to advance, 
self-evaluation within the community is critical. Here, we 
performed an interlaboratory comparison exercise for lipi-
domics using Standard Reference Material (SRM) 1950– 
Metabolites in Frozen Human Plasma, a commercially available 
reference material. The interlaboratory study comprised 31 
diverse laboratories, with each laboratory using a different 
lipidomics workflow. A total of 1,527 unique lipids were mea-
sured across all laboratories and consensus location esti-
mates and associated uncertainties were determined for 339 
of these lipids measured at the sum composition level by five 
or more participating laboratories. These evaluated lipids 
detected in SRM 1950 serve as community-wide benchmarks 
for intra- and interlaboratory quality control and method 
validation. These analyses were performed using nonstan-
dardized laboratory-independent workflows. The consensus 
locations were also compared with a previous examination 
of SRM 1950 by the LIPID MAPS consortium.  While the 
central theme of the interlaboratory study was to provide val-
ues to help harmonize lipids, lipid mediators, and precursor 
measurements across the community, it was also initiated to 
stimulate a discussion regarding areas in need of improve-
ment.—Bowden, J. A., A. Heckert, C. Z. Ulmer, C. M. Jones, 
J. P. Koelmel, L. Abdullah, L. Ahonen, Y. Alnouti, A. M. 
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The relationship between lipids and human health has 
been explored as early as the 1900s, where lipids were 
noted as important nutritional factors (1, 2) and were 
frequently found to be altered from homeostatic concen-
trations in pathophysiological conditions (3–5). Through-
out the century, lipids have been increasingly used to 
evaluate human health. However, it was not until the early 
2000s, with the advent of mass spectrometric approaches 
(6, 7), that the potential of lipid research could be realized. 
With the increased capacity to interrogate the lipidome, 
the number and types of human health applications em-
ploying lipid analysis have steadily risen (8–11). Over this 
period of rapid advancement, the lipidomics community, 
with leading endeavors from LIPID Metabolites and Pathways 
Strategy (LIPID MAPS), has pursued efforts to characterize 
several lipidomes, improve quantitative measurements, 
and delineate the complicated milieu of lipid interactions 
and pathways (12, 13). In 2010, LIPID MAPS formed a 
consortium to define the constituents of the mammalian 
lipidome using the National Institute of Standards and 
Technology (NIST) Standard Reference Material (SRM) 
1950–Metabolites in Frozen Human Plasma (14). The 
resulting lipidome was earmarked at 588 lipid species 
above error thresholds. This concerted effort was achieved 
piecemeal by separate core laboratories via contributions 
predominantly employing triple quadrupole MS technol-
ogy for targeted lipid class measurements.
Within the past 5 years, advances in chromatography 
and the advent of high-resolution MS have resulted in the 
measurement of a greater spectrum of lipids within the lipi-
dome using a single platform (15–17). With this enhanced 
coverage of the lipidome, there is an increased probability 
of characterizing lipid pathways perturbed by disease. This 
is supported by the dramatic increase in potential bio-
marker discovery applications in lipidomics using untar-
geted platforms (18, 19). However, as the lipidomics field 
expands from targeted assays, using predominantly triple 
quadrupole technology, to untargeted and perhaps back to 
targeted assays, using state of the art technology across a 
diverse range of workflows and platforms, it is important 
for the lipidomics community to monitor and improve 
measurement activities.
The same inherent qualities that lend themselves to the 
maturation of lipidomics and its widespread use as an 
approach to examine human health, namely the vast com-
plexity in lipid structure, function, and abundance and 
their ubiquitous existence at membrane, cellular, tissue, 
and systemic levels (20, 21), also imbue a variety of mea-
surement challenges. Despite these challenges, lipidomic 
studies continue to emerge at an increased rate and with a 
push toward precision medicine (22–26). However, a sub-
stantial roadblock in the progression of translating lipido-
mics from the bench to routine clinical settings is the lack 
of standardization or harmonization within the lipidomics 
community (27). Without standardization, the assessment 
of data quality independent of time, place, and procedure 
is difficult (28, 29). As the field of lipidomics continues to 
progress, it will be critical to be able to control, minimize, 
or, at the very least, understand intra- and interlaboratory 
variability to ensure confidence in the discovery of real bio-
logical differences (30, 31). Several excellent lipidomics 
reviews (15, 32–34) conclude that the differences in meth-
odology within the lipidomics community are extensive. 
This variation in lipidomics methodology has a direct 
impact on the resultant lipid profiles observed, affecting the 
number, type, and quantity of lipids observed (30, 31, 35). 
To date, the exact impact of this methodological diversity 
on community-wide lipid measurement and agreement is 
unknown.
Interlaboratory studies, where participants are instructed 
to perform a specific analysis on a homogenous and stable 
reference material followed by an evaluation and compari-
son of data at both an intra- and interlaboratory level, are 
exercises well-suited to critically evaluate the agreement of 
measurement within the lipidomics community and high-
light areas of concern. NIST and others have coordinated 
interlaboratory studies across disciplines for a wide variety 
of analytes, including omics-based profiles (36–43). For the 
latter, specifically for proteomics and metabolomics, inter-
laboratory studies have been presented with the theme of 
addressing the lack of agreement within the community by 
highlighting the need to develop standards, guidelines, 
and protocols, and to identify ways to evaluate laboratory 
performance, quality control, and dissemination (43–46). 
The paucity of commercially available reference materials 
for lipidomics and the lack of a reason to extend quality 
control practices beyond the intralaboratory level have lim-
ited the ability to benchmark data within the lipidomics 
community. The use of SRM 1950 as a control material for 
small molecule-based omics studies has been supported by 
a recent white paper on metabolomics-enabled precision 
medicine (47), where it is recommended that this certified 
reference material (CRM) be used as a material to aid in 
standardization and quality assessment across time and 
laboratories, at least until new reference materials are created. 
NIST produced this commercially available homogeneous 
material to aid in standardizing clinical measurements; 
other reports have noted its potential as a metabolomics 
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has equal value as a quality control sample for lipidomics 
and, thus, would be a suitable material for an interlabora-
tory comparison exercise.
Since 2014, NIST has been conducting an interlabora-
tory comparison exercise for lipidomics using SRM 1950. 
To provide a true cross-section of the lipidomics commu-
nity, 31 national and international laboratories, composed 
of both global and targeted lipidomic methodologies span-
ning across academia, industry, and core facilities, have 
participated. The interlaboratory study was designed to 
highlight: 1) the extent of agreement present in current 
lipidomic measurement within the community, 2) deter-
mine consensus locations with associated uncertainties for 
lipids present in SRM 1950, and 3) highlight the challenges 
present in current lipid measurements in regard to lipid 
methodology employed. In this work, we address the first 
two goals above; while a follow-up work will address meth-
odologies used and the effect on quantitation. Reference 
results have been established for 339 lipids present in SRM 
1950 that can be used by laboratories to assess whether 
their data agree with the lipidomics community. These 
consensus locations are compared with the concentration 
values noted from the LIPID MAPS consortium (14).
MATERIALS AND METHODS
SRM 1950
A vial of SRM 1950–Metabolites in Frozen Human Plasma was 
shipped on dry ice to participating laboratories. In collaboration 
with the National Institute of Diabetes and Digestive and Kidney 
Diseases, NIST developed SRM 1950 in 2006 as a “normal” human 
plasma reference material. A full description of this material is 
provided in its certificate of analysis (COA) (www.nist.gov/srm). 
In brief, this plasma material was constructed from 100 fasted in-
dividuals in the age range of 40–50 years, who represented the 
average composition of the US population, as defined by race, 
sex, and health (extreme health cohorts were excluded) (53). 
Due to these factors and its commercial availability, this material 
was selected for use in the interlaboratory lipidomics comparison 
exercise.
Overview of exercise
Participants in the exercise were provided a data submission 
template that contained several tabs focused on obtaining basic 
laboratory and method information: sample preparation, sample 
introduction and chromatography, mass spectrometric approach, 
and data processing. Unless the participant declined to disclose 
details, information was obtained on sample chain of custody, 
extraction methodology, internal standard selection, chromato-
graphic methods, mass spectrometer type, scanning approach 
employed (global and/or targeted), and the data handling/soft-
ware utilized. For the analysis of SRM 1950, each laboratory was 
asked to employ the analytical procedures traditionally used in 
their laboratories and to report lipids identified and quantified 
(in triplicate) at nanomoles per milliliter of plasma concentration 
levels. Laboratories were informed that all information, which 
could be used to link laboratories to their submitted data, would 
be excluded in the resulting publications.
The template, which also listed potential target lipid species, is 
reproduced in NIST Internal Report (IR) 8185 (54).
Organization of submitted data
Each participating laboratory submitted an Excel workbook 
that contained lipid identifications and the respective triplicate 
concentration measurements (nanomoles per milliliter). Upon 
receipt of data, the mean and standard deviation were calculated 
for lipids with three replicates and nonzero concentrations. Sub-
mitted data entries (lipid species name, m/z reported, and the ad-
duct utilized) were compared with LipidPioneer (55) for accuracy 
and consistency. Specifically, LipidPioneer was used to calculate 
the m/z of various adducts observed given the lipid name. Fea-
tures were flagged and researchers contacted if discrepancies 
were observed between the lipid name and the m/z reported. Sub-
mission errors found in lipid species assignment, mass assign-
ment, and/or adduct reported were edited and subsequently 
verified by the laboratory. Laboratories reported lipids by fatty acyl 
constituents and/or by the sum composition [total carbons:total 
double bonds, (C:DB)] according to the shorthand nomencla-
ture proposed by the International Lipid Classification and No-
menclature Committee (56). All entries were converted to sum 
composition for comparison across all laboratories. To accom-
plish this, concentrations for isomer lipid species per replicate 
were summed and the three replicate sums were used to calculate 
the mean and standard deviation. As an example, each replicate 
concentration of phosphatidylcholine PC(16:1_18:1) and 
PC(16:0_18:2) was summed and reported as PC(34:2). Lipid iso-
mers were included in the summation if they were reported by at 
least two laboratories.
Calculation of final consensus locations and uncertainties
The concept of calculating a consensus value and its associated 
uncertainty for measurements from multiple laboratories has 
been well-studied and there are many approaches available to 
address this challenge (57). We considered several methods for 
estimating the consensus location and associated uncertainty for 
each submitted lipid species. The consensus approach employed 
for this exercise was the median of means (MEDM) method (58). 
The MEDM consensus value (“location”) is simply the median of 
laboratory means. An associated standard uncertainty for the 
MEDM consensus value, u, is √(/2m) × 1.483 × MAD, where m 
and MAD denote the number of laboratories and the median ab-
solute deviation of the laboratory means, respectively (58). Analo-
gous to the sample coefficient of variation, the sample coefficient 
of dispersion (COD) (59), expressed as a percentage, was calcu-
lated as 100 × u/MEDM for each lipid species. These COD values 
were used to facilitate evaluation of the quality or “usefulness” of 
the consensus estimates. For evaluation purposes, the MEDMs 
were deemed acceptable for quality control activities if they had a 
COD value less than 40%.
The data in this study contained several extreme outliers (labo-
ratory mean lipid concentrations). These outliers violated the 
normality assumptions made by more statistically efficient con-
sensus estimation methods, such as Vangel-Rukhin (60, 61) and 
DerSimonian-Laird (DSL) (62)). The presence of these outliers 
resulted in unrepresentative consensus values for these two meth-
ods. However, the MEDM method generated reasonable and rep-
resentative consensus locations without requiring the omission of 
outlier laboratories from the analysis.
MEDM location estimates (nanomoles per milliliter) are only 
reported for lipids that were measured by at least five laboratories. 
NIST IR 8185 (54) details the consensus estimates and uncertain-
ties in both tabular and graphical formats.
Final consensus location comparison
The final consensus location estimates and the associated un-
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concentrations noted previously in the analysis of SRM 1950 con-
ducted by the LIPID MAPS consortium (14) using predominantly 
triple quadrupole technology for targeted lipid class measure-
ments. A percent change was calculated for lipids in SRM 1950, 
comparing the MEDM calculated in this study to the previously 
published values of the LIPID MAPS consortium. The values ob-
tained from the LIPID MAPS consortium were set as the refer-
ence values in the percent change calculation. The final MEDM 
lipid species were summed by class to reflect those lipids that were 
common to the LIPID MAPS consortium.
RESULTS AND DISCUSSION
Construction of the interlaboratory comparison exercise
Lipid measurements were obtained from a diverse collec-
tion of laboratories that represent the current cross-section 
of lipid measurement within the community. Invitations 
were sent to 100 potential participants, spanning labora-
tories with differing levels of experience, publication his-
tory, and lipid methodology. Of these, 31 laboratories 
submitted lipidomic data with one laboratory submitting 
two lipidomic data sets from different MS platforms. The 
participants consisted of 55% US/45% international-based, 
52% global/48% targeted profiling, and 78% academic/ 
22% commercial laboratories (representing industry and 
government entities). Global profiling laboratories are 
here defined as those laboratories reporting at least three 
lipid categories within a data submission. Targeted profil-
ing laboratories are defined here as those laboratories 
reporting values for lipids in less than three lipid categories. 
Lipid categories are classified as fatty acyls (FAs), glycero-
lipids (GLs), glycerophospholipids (GPs), polyketides, pre-
nol lipids, saccharolipids, sphingolipids (SPs), and sterols 
(STs) (63, 64).
Interlaboratory breakdown of the SRM 1950 plasma 
lipidome
Since the inception of lipidomics, there have been nu-
merous reports aimed at ascertaining the composition of 
the human plasma lipidome. Based on the degree of lipid 
identification (sum composition vs. individual isomers), it 
has been reported that anywhere between 150 and 700 
lipids could be present within the human plasma lipidome 
(14, 65–72). As lipidomic techniques advance, it is possible 
that many more lipids will be identified. The LIPID MAPS 
report on SRM 1950 in 2011, for example, employing tar-
geted class-specific analyses, noted 588 lipid species. At the 
sum composition level, 1,527 unique lipid identifications 
were reported in the current study. This value should be 
viewed conservatively, as it includes the sum of several 
isomeric lipid species. A breakdown of the lipid species 
reported, by lipid class, subclass, and number of labora-
tories reporting, can be found in NIST IR 8185 (54). The 
1,527 lipid species represent five lipid categories: FAs 
(n = 177), GLs (n = 317), GPs (n = 679), SPs (n = 236), 
and STs (n = 118).
Due to a high incidence of over-reporting observed 
within the study, lipid species were included in the final 
MEDM analysis only if reported by at least five laboratories 
(e.g., 745 lipids identified at the sum composition level 
were reported by only one laboratory). In total, there were 
339 lipids that were reported by 5 laboratories: FAs (n = 14), 
GLs (n = 83), GPs (n = 150), SPs (n = 58), and STs (n = 34). 
A dissection of the number of lipids by class for those lipids 
with MEDM values is shown in Fig. 1A. The final calculated 
MEDM with CODs 40% (n = 254) represent the most 
probable interval for which the true concentration value 
resides in SRM 1950, especially after factoring in the di-
verse methodologies employed by participating laborato-
ries. It should be noted that the participating laboratories 
applied independent protocols in this exercise and, hence-
forth, did not align their acquisition parameters, extrac-
tion protocols, or workflows in assessing the sample. While 
all laboratories employed different workflows, trends 
between MEDM location and COD and the number of 
laboratories reporting and COD were observed. The top-50 
most concentrated lipids with MEDM locations had an 
average COD of 26 ± 11% and were measured by an average 
Fig. 1. Lipid class composition of SRM 1950, according to num-
ber of lipid species (A) and concentration (B). Only lipid species 
that were measured by at least five participating laboratories are 
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of 15 ± 4 laboratories. Conversely, the bottom-50 least con-
centrated lipids with MEDM locations had an average COD 
of 35 ± 19% and were measured by an average of 7 ± 2 labo-
ratories. The COD values for the top-50 lipids, by concen-
tration, were significantly lower (P <0.005, two-sided t-test) 
than the bottom-50 lipids. In addition, the number of labo-
ratories reporting for a given lipid species was inversely 
proportional to the COD, as expected [see (54) for addi-
tional details].
Breakdowns of the consensus estimates organized by 
lipid category are presented for FAs (Table 1), GLs (Table 2), 
GPs (Table 3), SPs (Table 4), and STs (Table 5). The top 
five lipid classes using COD 40% criterion are: triacyl-
glycerols (TAGs) (n = 42), PCs (n = 53), SMs (n = 30), 
phosphatidylethanolamines (PEs) (n = 29), and lysophos-
phatidylcholines (LPCs) (n = 25). All major lipid classes 
are represented (Fig. 2). We endorse these consensus loca-
tions for use in quality control.
There were 97 lipids with COD 20%, representing sev-
eral lipid classes including: bile acids (BAs) (n = 6), choles-
teryl esters (CEs) (n = 2), ceramides (CERs) (n = 6), 
diacylglycerols (DAGs) (n = 1), eicosanoids (n = 1), free 
cholesterol (FC), FFAs (n = 2), LPCs (n = 13), PCs (n = 30), 
PEs (n = 12), phosphatidylinositols (PIs) (n = 12), SMs (n = 
6), and TAGs (n = 5). These data suggest that the commu-
nity measures phospholipids more consistently (specifi-
cally LPC, PC, PE, and PI species) relative to other lipid 
classes. Approximately, 52, 48, 34, and 80% of the LPC, PC, 
PE, and PI species, respectively, were measured with a 
COD 20%. However, for several of the lipids in the LPC 
class, even though the 40% COD criterion was satisfied, a 
significant number of laboratory means fell outside ±2 times 
the standard error of the consensus location estimate. Al-
though this can be explained by noting that the uncer-
tainty for the MEDM method is controlled by the 25% of 
the laboratory means both above and below the final 
MEDM estimate, some caution is warranted in using lipids 
from this class for quality control purposes.
There were 85 lipids with MEDM estimates associated 
with COD >40% (supplemental Tables S1–S5 for lipid cat-
egories FA, GL, GP, SP, and ST, respectively) in 13 lipid 
classes: CEs (n = 4), CERs (n = 7), FFAs (n = 6), DAGs (n = 19), 
hexosylceramides (HexCers) (n = 1), lysophosphatidyl-
ethanolamines (LPEs) (n = 2), PCs (n = 10), PEs (n = 6), 
phosphatidylglycerols (PGs) (n = 2), PIs (n = 2), phosphati-
dylserines (PSs) (n = 1), SMs (n = 8), and TAGs (n = 17). 
The classes with the greatest percentage of lipids with 
COD >40% were CERs (40%), DAGs (79%), FFAs (54%), 
and TAGs (28%). These findings lend greater insight into 
the lipids and lipid classes most affected by measurement 
diversity and emphasize a need to improve measurement 
uniformity. The lipids with COD >40% should not be used 
for quality control; rather, we suggest that these lipids and 
lipid classes represent challenges requiring improvement 
in lipid measurement.
By lipid class, the largest overall lipid concentration us-
ing the lipids having MEDM values was attributed to CEs 
(47%), PCs (18%), cholesterol (12%), TAGs (9%), and 
SMs (5%), as shown in Fig. 1B. The lipid category with the 
fewest MEDM values was the fatty acyls, which comprised 
FFAs (n = 11) and eicosanoids (n = 3), as shown in Table 1. 
As part of this exercise, SRM 1950 was sent to nine targeted 
laboratories for eicosanoid measurement. Eicosanoids are 
defined here as lipid mediator analogs produced from 
polyunsaturated fatty acids. Only six laboratories provided 
eicosanoid concentrations (two laboratories were not able 
to measure any eicosanoids in SRM 1950, one laboratory 
failed to respond). In total, 143 eicosanoids were measured 
by at least one laboratory; however, only three (5-HETE, 
12-HETE, and 15-HETE) were measured by at least five 
laboratories.
Table 2 lists the MEDM estimates for two lipid classes of 
the GL category: DAGs (n = 24) and TAGs (n = 59). Table 
3 lists the estimates for the numerous lipids of several 
classes in the GP category, including LPCs (n = 25), LPEs 
(n = 8), PCs (n = 63), PEs (n = 35), PGs (n = 3), PIs (n = 15), 
and PSs (n = 1). Table 4 lists the estimates for three classes 
in the SP category, including CERs (n = 15), HexCers (n = 5), 
and SMs (n = 38). Table 5 lists the estimates for the ST cat-
egory, including CEs (n = 19), BAs (n = 14), and FC. These 
ST lipids represent about 59% of the total lipid concentra-
tion of SRM 1950 (See Fig. 1B).
Additional consensus location values for those lipids 
with only three to four laboratories reporting (n = 192) are 
listed in supplemental Table S6 to expand the lipidome 
coverage for SRM 1950. These “tentative” values are calcu-
lated using the DSL estimator, which is more reliable than 
the MEDM with small numbers of normally distributed 
data (62). For inclusion as a tentative location, we set the 
criteria at having a DSL-based COD 40% and the percent 
difference between the DSL and MEDM estimates 20%. 
There were 62 lipids that fit this criterion (supplemental 
TABLE 1. Final consensus location estimates for fatty acyl (FA) lipids measured in SRM 1950
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
FFA 16:0 5 nmol/ml 43 13 31
FFA 18:3 6 nmol/ml 2.9 0.62 21
FFA 20:4 7 nmol/ml 4.7 1.5 31
FFA 20:5 7 nmol/ml 0.42 0.056 13
FFA 22:6 8 nmol/ml 1.5 0.17 11
5-HETE 5 pmol/ml 10 1.3 13
12-HETE 5 pmol/ml 6.8 1.5 23
15-HETE 5 pmol/ml 2.4 0.64 27
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used to evaluate different sources of variability (e.g., sample 
preparation, instrumental data acquisition, and analysis), 
determine the long-term robustness of measurement pro-
cesses, and validate methods (73). SRM 1950 is a CRM pro-
duced by NIST with certified reference values for amino 
acids, cholesterol, vitamins, total fatty acids, and other clini-
cal markers. While the consensus values generated for SRM 
1950 in this interlaboratory study are not certified, the val-
ues are a cross-section of measurements obtained within 
the lipidomics community using a CRM with which 
researchers can assess measurement methodology (e.g., 
quantitation performance). The calculated consensus loca-
tions provide the lipidomics community with the opportu-
nity to extend quality control activities beyond the typical 
practices performed internally using in-house materials. On 
a wider scale, SRM 1950 has 339 robustly measured lipids 
Table S6), largely represented by eicosanoids (n = 20) and 
TAGs (n = 7). One lipid with a tentative value was total 
cholesterol, which has a NIST-certified concentration of 
3,917 ± 85 nmol/ml reported on the SRM 1950 COA. The 
DSL estimate for total cholesterol, as calculated using the 
interlaboratory submissions, was 3,980 ± 24 nmol/ml, 
which was within the uncertainty of the certified reference 
value note on the COA.
Usefulness of final consensus values
CRMs are widely employed to assess measurement meth-
odologies. For example, a laboratory can have confidence 
that the process or method employed provided a quality 
measurement if their measured value agrees with the certi-
fied value within the combined uncertainties of the mea-
sured and certified values. Moreover, CRMs can also be 
TABLE 2. Final consensus location estimates for GLs measured in SRM 1950
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
DAG 30:0 7 nmol/ml 0.83 0.17 20
DAG 34:1 16 nmol/ml 6.1 2.4 40
DAG 36:2 16 nmol/ml 6.2 2.2 36
DAG 36:3 15 nmol/ml 8.4 3.3 39
DAG 36:4 12 nmol/ml 2.8 1.0 38
TAG 46:2 8 nmol/ml 3.6 1.3 37
TAG 48:0 10 nmol/ml 4.5 1.2 26
TAG 48:1 16 nmol/ml 13 3.2 24
TAG 48:2 15 nmol/ml 16 2.8 18
TAG 48:4 5 nmol/ml 1.3 0.23 18
TAG 49:1 9 nmol/ml 2.0 0.42 21
TAG 49:2 6 nmol/ml 1.8 0.56 31
TAG 50:0 11 nmol/ml 3.8 0.83 22
TAG 50:1 14 nmol/ml 38 10 26
TAG 50:2 15 nmol/ml 47 12 26
TAG 50:3 16 nmol/ml 23 6.6 29
TAG 50:4 15 nmol/ml 8.7 2.9 34
TAG 50:5 7 nmol/ml 1.6 0.64 40
TAG 51:1 7 nmol/ml 1.8 0.48 27
TAG 51:2 8 nmol/ml 4.8 1.1 22
TAG 51:3 5 nmol/ml 4.8 1.9 39
TAG 52:1 11 nmol/ml 14 2.9 20
TAG 52:2 16 nmol/ml 44 14 33
TAG 52:3 16 nmol/ml 100 29 28
TAG 52:4 15 nmol/ml 48 17 35
TAG 52:5 13 nmol/ml 15 5.7 39
TAG 52:6 8 nmol/ml 4.0 1.4 35
TAG 52:7 5 nmol/ml 0.39 0.13 33
TAG 53:2 9 nmol/ml 1.9 0.41 21
TAG 53:3 6 nmol/ml 3.7 1.1 29
TAG 53:4 6 nmol/ml 2.4 0.76 32
TAG 54:1 10 nmol/ml 3.2 0.91 29
TAG 54:2 13 nmol/ml 8.2 2.6 31
TAG 54:3 15 nmol/ml 26 9.8 37
TAG 54:4 15 nmol/ml 36 13 35
TAG 54:5 15 nmol/ml 27 11 38
TAG 54:6 16 nmol/ml 14 5.1 37
TAG 54:7 7 nmol/ml 5.6 1.5 26
TAG 56:2 5 nmol/ml 0.69 0.23 33
TAG 56:3 6 nmol/ml 1.4 0.14 10
TAG 56:4 10 nmol/ml 2.0 0.56 28
TAG 56:5 12 nmol/ml 4.1 1.4 33
TAG 56:7 8 nmol/ml 13 2.7 20
TAG 56:9 5 nmol/ml 0.71 0.27 38
TAG 58:7 5 nmol/ml 2.0 0.64 32
TAG 58:8 9 nmol/ml 0.68 0.21 31
TAG 58:9 6 nmol/ml 1.2 0.27 22
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TABLE 3. Final consensus location estimates for GPs measured in SRM 1950
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
LPC 14:0 16 nmol/ml 1.0 0.20 19
LPC 15:0 9 nmol/ml 0.52 0.11 22
LPC 16:0 20 nmol/ml 73 11 15
LPC O-16:0 10 nmol/ml 0.55 0.16 29
LPC P-16:0 8 nmol/ml 0.46 0.13 27
LPC 16:1 19 nmol/ml 2.4 0.35 15
LPC 17:0 6 nmol/ml 1.4 0.24 18
LPC 17:1 6 nmol/ml 0.25 0.071 29
LPC 18:0 20 nmol/ml 27 3.3 12
LPC O-18:0 6 nmol/ml 0.16 0.058 36
LPC 18:1 19 nmol/ml 18 2.3 13
LPC 18:2 19 nmol/ml 22 2.9 13
LPC 18:3 18 nmol/ml 0.44 0.13 30
LPC 20:0 7 nmol/ml 0.10 0.034 34
LPC 20:1 13 nmol/ml 0.19 0.024 12
LPC 20:2 9 nmol/ml 0.23 0.044 19
LPC 20:3 18 nmol/ml 1.8 0.26 15
LPC 20:4 20 nmol/ml 6.0 0.60 10
LPC 20:5 15 nmol/ml 0.33 0.092 28
LPC 22:0 5 nmol/ml 0.025 0.0017 7
LPC 22:1 5 nmol/ml 0.013 0.0046 36
LPC 22:4 8 nmol/ml 0.12 0.041 33
LPC 22:5 12 nmol/ml 0.43 0.13 30
LPC 22:6 17 nmol/ml 0.77 0.14 18
LPC 24:0 5 nmol/ml 0.046 0.015 33
LPE 16:0 14 nmol/ml 0.91 0.27 29
LPE 18:0 15 nmol/ml 1.6 0.55 34
LPE 18:1 14 nmol/ml 1.4 0.47 35
LPE 18:2 16 nmol/ml 1.9 0.56 30
LPE 20:4 14 nmol/ml 1.1 0.41 37
LPE 22:6 12 nmol/ml 0.52 0.18 34
PC 30:0 11 nmol/ml 1.6 0.32 20
PC O-30:0/29:0 7 nmol/ml 0.072 0.026 36
PC O-30:1/P-30:0 7 nmol/ml 0.047 0.0096 20
PC 32:0 18 nmol/ml 7.2 1.0 14
PC O-32:0/31:0 11 nmol/ml 1.5 0.41 28
PC 32:1 18 nmol/ml 13 1.9 15
PC O-32:1/P-32:0/31:1 11 nmol/ml 1.6 0.24 14
PC O-32:2/P-32:1/31:2 8 nmol/ml 0.34 0.093 28
PC 32:3 8 nmol/ml 0.42 0.14 34
PC P-33:1/32:2 16 nmol/ml 2.6 0.37 14
PC 34:0 12 nmol/ml 2.1 0.37 18
PC O-34:0/33:0 10 nmol/ml 0.76 0.17 22
PC 34:1 19 nmol/ml 120 21 17
PC O-34:1/P-34:0/33:1 17 nmol/ml 4.9 0.86 17
PC O-34:2/P-34:1/33:2 17 nmol/ml 5.2 1.3 25
PC O-34:3/P-34:2/33:3 12 nmol/ml 4.7 0.88 19
PC P-35:1/34:2 18 nmol/ml 240 47 19
PC P-35:2/34:3 18 nmol/ml 12 1.7 14
PC O-35:4/34:4 9 nmol/ml 1.0 0.25 24
PC 34:5 5 nmol/ml 0.034 0.0045 13
PC 36:1 17 nmol/ml 26 4.6 17
PC O-36:1/P-36:0/35:1 16 nmol/ml 3.5 0.99 28
PC 36:2 18 nmol/ml 140 25 17
PC O-36:2/P-36:1/35:2 17 nmol/ml 7.4 1.7 22
PC 36:3 17 nmol/ml 100 14 14
PC O-36:3/P-36:2/35:3 12 nmol/ml 3.7 0.82 22
PC 36:4 19 nmol/ml 150 28 19
PC O-36:4/P-36:3/35:4 17 nmol/ml 12 1.4 12
PC 36:5 16 nmol/ml 11 1.8 17
PC O-36:5/P-36:4/35:5 11 nmol/ml 6.9 1.6 23
PC P-36:5/35:6 5 nmol/ml 0.30 0.094 31
PC 36:6 8 nmol/ml 0.28 0.088 32
PC 38:2 15 nmol/ml 2.3 0.20 9
PC O-38:2/37:2 6 nmol/ml 0.98 0.32 32
PC 38:3 14 nmol/ml 26 5.2 20
PC O-38:3/P-38:2/37:3 14 nmol/ml 1.5 0.51 34
PC 38:4 18 nmol/ml 84 14 17
PC O-38:4/P-38:3/37:4 12 nmol/ml 7.4 2.0 27
PC 38:5 18 nmol/ml 42 7.9 19
PC O-38:5/P-38:4/37:5 16 nmol/ml 11 1.6 14
PC 38:6 18 nmol/ml 41 4.4 11
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(by sum composition), which can help to benchmark lipid 
measurement within the community. A new automated 
lipid validation tool, LipidQC, has been introduced (J. A. 
Bowden, unpublished observations), which allows users to 
rapidly compare their experimental SRM 1950 lipid con-
centrations to the consensus estimates generated from this 
interlaboratory exercise. Use of SRM 1950 for quality con-
trol can now be a first step toward community-wide harmo-
nization, which is a vital component in uncovering the full 
potential of lipidomics in clinical science.
Comparison of consensus locations to LIPID MAPS 
consortium concentrations
The calculated consensus values were compared with the 
lipid concentrations noted in a report by Quehenberger 
et al. (14) where lipids were investigated in SRM 1950 by 
several members of the LIPID MAPS consortium using 
targeted (class-specific) methods. It is important to note that 
this interlaboratory study was unique in that the LIPID 
MAPS study only employed a single expert laboratory for 
each lipid class using predominantly triple quadrupole 
TABLE 3. Continued.
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
PC P-38:6/36:0 10 nmol/ml 1.2 0.39 33
PC 40:4 18 nmol/ml 2.9 0.37 13
PC O-40:2/P-40:1 5 nmol/ml 0.069 0.021 30
PC O-40:4/P-40:3/39:4 8 nmol/ml 0.95 0.38 40
PC 40:5 18 nmol/ml 6.7 1.1 16
PC O-40:5/P-40:4/39:5 12 nmol/ml 1.7 0.45 27
PC 40:6 17 nmol/ml 14 2.6 19
PC 40:7 16 nmol/ml 3.5 0.76 21
PC O-40:7/P-40:6/39:7 9 nmol/ml 1.1 0.23 20
PC 40:8 14 nmol/ml 0.73 0.20 28
PC O-42:5/P-42:4 7 nmol/ml 0.79 0.12 15
PE 32:1 6 nmol/ml 0.34 0.12 36
PE 34:1 14 nmol/ml 1.2 0.17 14
PE 34:2 16 nmol/ml 2.2 0.26 12
PE O-34:2/P-34:1 11 nmol/ml 0.78 0.17 22
PE O-34:3/P-34:2 11 nmol/ml 1.5 0.41 27
PE 36:0 11 nmol/ml 0.28 0.10 36
PE 36:1 14 nmol/ml 1.3 0.26 20
PE 36:2 16 nmol/ml 6.7 0.79 12
PE O-36:2/P-36:1/35:2 12 nmol/ml 0.93 0.22 23
PE 36:3 16 nmol/ml 2.4 0.38 16
PE O-36:3/P-36:2/35:3 15 nmol/ml 3.2 0.76 24
PE 36:4 16 nmol/ml 3.1 0.39 13
PE O-36:4/P-36:3 14 nmol/ml 1.6 0.29 18
PE O-36:5/P-36:4 15 nmol/ml 4.9 1.9 38
PE 38:3 14 nmol/ml 0.95 0.20 21
PE 38:4 16 nmol/ml 8.1 1.2 15
PE O-38:4/P-38:3/37:4 9 nmol/ml 0.94 0.18 19
PE 38:5 12 nmol/ml 2.7 0.47 17
PE O-38:5/P-38:4 17 nmol/ml 5.8 1.9 33
PE 38:6 15 nmol/ml 3.2 0.59 19
PE O-38:6/P-38:5 16 nmol/ml 4.9 1.2 25
PE O-38:7/P-38:6 8 nmol/ml 3.5 0.98 28
PE 40:4 10 nmol/ml 0.26 0.082 31
PE 40:5 12 nmol/ml 0.73 0.23 31
PE O-40:5/P-40:4/39:5 12 nmol/ml 0.73 0.13 17
PE 40:6 14 nmol/ml 1.8 0.36 20
PE O-40:6/P-40:5/39:6 14 nmol/ml 1.3 0.31 23
PE 40:7 11 nmol/ml 0.77 0.26 33
PE O-40:7/P-40:6/39:7 14 nmol/ml 2.5 0.72 29
PI 32:1 10 nmol/ml 0.56 0.11 19
PI 34:1 14 nmol/ml 2.4 0.42 17
PI 34:2 14 nmol/ml 2.8 0.38 14
PI 36:1 13 nmol/ml 2.1 0.59 28
PI 36:2 15 nmol/ml 7.7 0.93 12
PI 36:3 14 nmol/ml 2.2 0.29 14
PI 36:4 14 nmol/ml 3.0 0.48 16
PI 38:3 14 nmol/ml 3.4 0.54 16
PI 38:4 17 nmol/ml 19 2.2 11
PI 38:5 15 nmol/ml 2.5 0.44 18
PI 38:6 10 nmol/ml 0.32 0.031 10
PI 40:4 7 nmol/ml 0.30 0.042 14
PI 40:6 12 nmol/ml 0.84 0.16 19
PG 36:2 6 nmol/ml 0.67 0.24 36
MEDM consensus estimates shown were calculated for those lipids measured by at least five laboratories and had 
COD values 40%. For PC and PE lipid classes, the isobaric species (ether-linked) were summed and the possibilities 
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technology. Therefore, the LIPID MAPS study did not pro-
vide information on the state of lipid measurements across 
the community at large or include methods using both 
targeted and untargeted workflows with the latest instru-
mentation. In total, the LIPID MAPS study reported 588 
lipids in SRM 1950 from several lipid classes, while the in-
terlaboratory exercise reported 1,527 individual lipid species. 
A comparison of the reported LIPID MAPS species to those 
reported in the interlaboratory exercise (by five or more 
laboratories) resulted in 226 overlapping lipid species.
A comparison of these overlapping species, organized by 
lipid class, is shown in supplemental Tables S7–S16. The 
individual MEDM and LIPID MAPS study values were also 
summed by lipid class and the results (derived values in 
supplemental Table S17) were compared in Fig. 3A (high 
concentration lipids) and Fig. 3B (low concentration lipids). 
The sum of the 226 lipids in common from the LIPID 
MAPS study (8,438 ± 106 nmol/ml) was significantly higher 
than that of the same lipid species determined in this exer-
cise (6,218 ± 475 nmol/ml). As shown in Fig. 3A, B, this 
difference was driven mostly by PC, PE, and TAG species. 
The main contributors to the difference between the two 
studies were phospholipids and, to a lesser extent, nonpo-
lar lipids. This coincided with a large percent change in the 
interlaboratory consensus estimates relative to the LIPID 
MAPS measurements, with percent changes: LPCs (+48%), 
LPEs (80%), PCs (56%), PEs (83%), PIs (+58%), and 
TAGs (54%). In addition to methodological differences, 
reporting at the sum composition level might contribute to 
some of these differences, as the isomer lipids contributing 
to the sums may not be the same. Overall, the total lipid 
content for common lipids showed that the LIPID MAPS 
sum was 30% larger than the summed composition of com-
mon lipids that were determined in this exercise, signifying 
a difference in measurement effects between studies, an 
aspect that will be addressed with future efforts.
Future of lipidomic quantitation
To date, no clear community-wide consensus exists for the 
best approach to quantify lipids. Quantitation in lipidomics 
TABLE 4. Final consensus location estimates for SPs measured in SRM 1950
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
HexCer d34:1 6 nmol/ml 0.86 0.21 25
HexCer d36:1 5 nmol/ml 0.13 0.043 34
HexCer d40:1 5 nmol/ml 2.4 0.68 28
HexCer d42:1 6 nmol/ml 2.7 0.73 27
CER d34:1 17 nmol/ml 0.28 0.044 16
CER d36:1 14 nmol/ml 0.12 0.021 17
CER d38:1 16 nmol/ml 0.11 0.021 20
CER d40:1 18 nmol/ml 0.65 0.12 18
CER d40:2 6 nmol/ml 0.15 0.021 14
CER d41:1 7 nmol/ml 0.67 0.27 40
CER d42:1 19 nmol/ml 1.9 0.47 24
CER d42:2 19 nmol/ml 0.82 0.10 12
SM d31:1 5 nmol/ml 0.19 0.049 25
SM d32:1 14 nmol/ml 8.4 1.4 17
SM d32:2 10 nmol/ml 0.66 0.24 36
SM d33:1 14 nmol/ml 4.7 0.64 14
SM d34:0 14 nmol/ml 5.8 1.3 22
SM d34:1 21 nmol/ml 100 15 15
SM d34:2 17 nmol/ml 16 2.2 14
SM d35:1 9 nmol/ml 2.5 0.58 23
SM d35:2 6 nmol/ml 0.52 0.21 39
SM d36:0 11 nmol/ml 2.0 0.49 24
SM d36:1 22 nmol/ml 20 3.7 18
SM d36:2 22 nmol/ml 9.6 1.5 16
SM d36:3 13 nmol/ml 1.3 0.41 31
SM d37:1 11 nmol/ml 1.0 0.23 23
SM d38:1 17 nmol/ml 11 3.1 27
SM d38:2 17 nmol/ml 5.2 1.3 25
SM d38:3 8 nmol/ml 0.61 0.24 39
SM d39:1 14 nmol/ml 3.6 1.0 29
SM d39:2 9 nmol/ml 0.61 0.16 26
SM d40:1 17 nmol/ml 20 5.1 25
SM d40:2 15 nmol/ml 12 2.8 24
SM d40:3 8 nmol/ml 2.2 0.79 37
SM d41:1 14 nmol/ml 7.7 2.1 27
SM d41:2 14 nmol/ml 5.8 1.4 24
SM d41:3 7 nmol/ml 0.77 0.30 39
SM d42:1 21 nmol/ml 20 5.4 28
SM d42:2 18 nmol/ml 44 11 25
SM d42:3 12 nmol/ml 17 4.7 27
SM d43:2 10 nmol/ml 1.0 0.29 29
SM d44:2 9 nmol/ml 0.40 0.13 32
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is a polarizing subject within the community, with both 
methodological and philosophical differences to consider. 
The community has limited agreement on the definition 
of current quantitation approaches (absolute, semi-, and 
relative) and determination of the essential guidelines to 
perform each approach. Furthermore, the discussion of 
quantitation becomes more convoluted when assessing 
strategies for both targeted and global profiling approaches 
because neither has been explicitly studied. There is a 
quantitation tradeoff between these two approaches. Gen-
erally, targeted approaches employ calibration curves and 
appropriate standards, which improve quantitation, while 
global approaches typically provide more lipid identifica-
tions in a single analysis. Even in targeted studies for lipido-
mics, appropriate standards are often not available and 
single point calibration is commonly used. The lipidomics 
community is implementing relative quantitation experi-
ments to increase accuracy in untargeted studies, with a 
focus on monitoring lipid species changes between sample 
groups rather than determining the exact concentration 
of lipids (74–76). Laboratories generally employ semi-
quantitative approaches to provide concentrations for lipid 
species; however, several assumptions are generally made 
using this approach (32, 76–78).
One major impediment to uniform quantitation within 
the community is the lack of suitable internal standards. To 
date, several different types of internal standards have been 
employed (odd-chained, deuterated, or 13C-labeled), but 
each has limitations. Ideally, multiple internal standards 
should be employed for all types and classes of lipids to 
improve quantitation. However, the availability of lipids 
that can serve as internal standards is limited. In this study, 
the specific internal standards utilized largely influenced 
the reported final lipid concentration. For example, if a 
laboratory quantified a lipid class with an internal standard 
TABLE 5. Final consensus location estimates for ST lipids measured in SRM 1950
Lipid Number of Laboratories Units Consensus Location Standard Uncertainty COD (%)
CE 14:0 7 nmol/ml 16 6.0 37
CE 15:0 6 nmol/ml 5.3 1.8 34
CE 16:0 13 nmol/ml 210 58 28
CE 16:1 11 nmol/ml 100 27 27
CE 16:2 5 nmol/ml 1.9 0.46 25
CE 17:1 9 nmol/ml 8.2 1.0 13
CE 18:0 7 nmol/ml 15 3.7 25
CE 18:1 14 nmol/ml 450 110 25
CE 18:2 14 nmol/ml 1,700 430 26
CE 18:3 13 nmol/ml 84 24 28
CE 20:3 13 nmol/ml 35 12 35
CE 20:4 14 nmol/ml 350 58 17
CE 20:5 12 nmol/ml 38 8.6 23
CE 22:5 6 nmol/ml 4.1 1.6 39
CE 22:6 11 nmol/ml 37 9.5 26
Cholesterol 8 nmol/ml 770 110 14
CDCA 7 nmol/ml 0.30 0.11 38
CA 9 nmol/ml 0.12 0.034 28
DCA 9 nmol/ml 0.35 0.083 24
GCDCA 8 nmol/ml 1.1 0.18 17
GDCA 7 nmol/ml 0.43 0.069 16
GLCA 6 nmol/ml 0.025 0.0018 7
GUDCA 6 nmol/ml 0.15 0.024 16
GCA 6 nmol/ml 0.24 0.069 29
LCA 8 nmol/ml 0.014 0.0036 26
TCDCA 9 nmol/ml 0.084 0.0050 6
TCA 9 nmol/ml 0.026 0.0056 22
TDCA 8 nmol/ml 0.040 0.0064 16
TLCA 5 nmol/ml 0.0027 0.00069 26
UDCA 8 nmol/ml 0.11 0.024 22
CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glyocholic acid; GCDCA, 
glycochenodeoxycholic acid; GDCA, glycodeoxycholic acid; GLCA, glycolithocholic acid; GUDCA, 
glycoursodeoxycholic acid; LCA, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; 
TDCA, taurodeoxycholic acid; TLCA, taurolithocholic acid; UDCA, ursodeoxycholic acid. MEDM consensus 
estimates shown were calculated for those lipids measured by at least five laboratories and had COD values 40%.
Fig. 2.  COD (in percent) for the MEDM lipids (n  5 laborato-
ries reporting) organized by lipid class. Each point on the figure 
represents a single sum lipid composition. The COD was calculated 
by dividing the standard uncertainty by the final MEDM. CODs not 
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from a different class, often the concentration values were 
quite different from those obtained from laboratories 
using standards from the appropriate lipid class. We found 
that several odd-chain lipids, often used by laboratories as 
exogenous internal standards, were reported as endoge-
nous lipids by participating laboratories in this exercise 
(e.g., CE 17:0, n = 6; LPC 17:0, n = 6; SM d35:1, n = 9; and 
TAG 51:3, n = 5; n indicates number of incidences).
Comparing the consensus values from this exercise (using 
a variety of quantitation MS platforms: triple quadrupole, 
quadrupole time-of-flight, and Orbitrap) to the concentra-
tion values obtained using the targeted triple quadrupole 
platforms, we found that the targeted approaches generally 
had significantly higher calculated concentration values. 
Future studies will further explore the contribution of 
analytical platforms and lipidomics workflows to the final 
concentration calculated using the interlaboratory data. As 
the community begins to develop and establish guidelines 
for quality assurance and quality control, discussions need 
to include acceptable practices for quantitation across the 
varying platforms present within the lipidomics community.
CONCLUSIONS
The purpose of this lipidomic interlaboratory compari-
son exercise was to identify the metrological questions 
and/or gaps that exist in current lipidomic measurement. 
To determine the principal areas of need, the interlabora-
tory exercise was initiated using a commercially available 
CRM, SRM 1950. This interlaboratory study provides an 
initial outlook into the variance associated with current 
lipid methodologies. The robustly measured SRM 1950 
consensus estimates can be used for community-wide qual-
ity control and quality assessment. These values were com-
pared with those previously reported by LIPID MAPS, with 
significant discrepancies for specific lipid classes between 
both studies, and thus require further attention to under-
stand the reasons behind this difference. From a commu-
nity perspective, the exercise also provided valuable insight 
into the potential strengths and weaknesses of current 
lipidomic measurement. Future efforts resulting from this 
interlaboratory study will focus on making the data avail-
able to the community and examining the influence that 
the laboratory-provided methodology had on the resultant 
trends in the collective data. We currently intend to pro-
vide a supplemental survey to direct future measurement 
efforts regarding lipidomic measurement.
The authors would like to thank Kayla Carter (US Center for 
Disease Control and Prevention), Debra Ellisor (NIST), John 
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